All In Biotech

Drug Trial Radar · NCT04984512

The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

A Phase II/III ,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Adaptive Design Study Evaluating the Efficacy And Safety of Mitizodone Phosphate Tablets in the Treatment of Patient With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Dec 14, 2021

Primary completion

Jul 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.

Conditions

  • Depressive Disorder, Major

Interventions

  • Mitizodone Phosphate tabletsDrug

    Mitizodone Phosphate tablets will be administered with food.

  • Placebo-matching tabletsDrug

    Placebo will be administered with food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 8Time frame: baseline and week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sunshine Lake Pharma Co., Ltd.

    Dongguan, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.